Pyrazoline-based mycobactin analogues as dual inhibitors of MAO/cholinesterase;MAO ve kolinesteraz dual i̇nhibitörü pirazolin-bazli mikobaktin analoglari]

Turkish Journal of Biochemistry

Volumn 35, Issue 2, 2010, Pages 91-98

  Jayaprakash, Venkatesan ^a   Yabanoglu, Samiye ^b   Sinha, Barij N ^a   Ucar, Gulberk ^b  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Aryl carbothioamide pyrazolines; MAO inhibitors; Mycobactin analogues

Indexed keywords

1 CARBOTHIOAMIDE PYRAZOLINE DERIVATIVE; ACETYLCHOLINE; AMINE OXIDASE (FLAVIN CONTAINING); CHOLINESTERASE; CHOLINESTERASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MYCOBACTIN DERIVATIVE; PYRAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG SELECTIVITY; EEL; ENZYME INHIBITOR INTERACTION; HORSE; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

RATTUS;

EID: 77954755639     PISSN: None     EISSN: 1303829X     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Schmitt B, Bernhardt T, Moeller HJ, Heuser I, Frolich L (2004) Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs 18: 827-844.
2. Giacobini E. (2003) Cholinergic function and Alzheimer's disease. Int. J. Geriatr. Psychiatry 18: S1-5.
3. Shintani EY, Uchida KM. (1997) Donepezil: an anticholinesterase inhibitor for Alzheimer's disease, Am. J. Health Syst. Pharm. 54, 2805-2810.
4. [4] Birks J. (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 1, CD00559.
5. Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, Rockwood K, Martin E. (2003) Inhibition of human cholinester-ases by drugs used to treat Alzheimer disease. Alzheimer Dis. Assoc. Disord. 17(2):117-1126.
6. Morphy R, Rankovic Z. (2005) Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48(21):6523-6543.
7. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C. (2008) Multi-target-directed li gands to combat neurodegenerative diseases. J. Med. Chem. 51(3):347-372.
8. Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M. (2006) Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neu-roprotective-neurorescue drugs; ladostigil. Neurotox. Res. 10(3-4):181-192.
9. [9] Ucar G, Gokhan N, Yesilada A, Bilgin AA. (2005) 1-W-Substi-tuted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci. Lett. 382(3):327-331.
10. Stirrett KL, Ferreras JA, Jayaprakash V, Sinha BN, Ren T, Quadri LE. (2008) Small molecules with structural similarities to siderophores as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis. Bioorg. Med. Chem. Lett. 18(8): 2662-2668.
11. Jayaprakash V, Sinha BN, Ucar G, Ercan A. (2008) Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorg. Med. Chem. Lett. 18(24): 6362-6368.
12. Ellman GL, Courtney KD, Andres Jr. V, Featherstone RM. (1961) A new and rapid colorimetric determination of acetylcho-linesterase activity. Biochem. Pharmacol. 7(2):88-95.
13. Eyer P, Worek F, Kiderlen D, Sinko G, Stuglin A, Simeon-Rudolf V, Reiner E. (2003) Molar absorption coefficients for the reduced Ellman reagent: reassessment. Anal. Biochem. 312(2): 224-227.